ilmscore | Prediction Details
"four of which are in phase two and expecting results within the next two quarters"
By Let's Talk Money! with Joseph Hogue, CFA | June 14, 2024 | Pending
From video
7 AI Stocks to Buy Revolutionizing Healthcare 00:12:40 - 00:12:44
Interpreted Prediction
Recursion Pharmaceuticals (RXRX) is expecting results for four of its Phase 2 pipeline trials within the next two quarters (Q3 and Q4 of 2024).

Prediction Details

Ticker
RXRX
Initial Price
9.26 USD

Comments

Be the first to share your thoughts.

Like this prediction?

Join to make your opinion count.